These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 39068716)

  • 1. Design, synthesis, and biological evaluation of β-carboline-cinnamic acid derivatives as DYRK1A inhibitors in the treatment of diabetes.
    Guan L; Li A; Song P; Su W; Zhang S; Chen J; Jiao X; Li W
    Bioorg Chem; 2024 Oct; 151():107676. PubMed ID: 39068716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
    Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
    Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization.
    Allegretti PA; Horton TM; Abdolazimi Y; Moeller HP; Yeh B; Caffet M; Michel G; Smith M; Annes JP
    Bioorg Med Chem; 2020 Jan; 28(1):115193. PubMed ID: 31757680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.
    Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ
    Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational & experimental evaluation of the structure/activity relationship of β-carbolines as DYRK1A inhibitors.
    Drung B; Scholz C; Barbosa VA; Nazari A; Sarragiotto MH; Schmidt B
    Bioorg Med Chem Lett; 2014 Oct; 24(20):4854-60. PubMed ID: 25240617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic Kinome Inhibitors-A New Opportunity for β-Cells Restoration.
    Pucelik B; Barzowska A; Dąbrowski JM; Czarna A
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.
    Kumar K; Wang P; Wilson J; Zlatanic V; Berrouet C; Khamrui S; Secor C; Swartz EA; Lazarus M; Sanchez R; Stewart AF; Garcia-Ocana A; DeVita RJ
    J Med Chem; 2020 Mar; 63(6):2986-3003. PubMed ID: 32003560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.
    Kumar K; Wang P; Sanchez R; Swartz EA; Stewart AF; DeVita RJ
    J Med Chem; 2018 Sep; 61(17):7687-7699. PubMed ID: 30059217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition-The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid Harmine.
    Wurzlbauer A; Rüben K; Gürdal E; Chaikuad A; Knapp S; Sippl W; Becker W; Bracher F
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33339338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational Design and Identification of Harmine-Inspired, N-Heterocyclic DYRK1A Inhibitors Employing a Functional Genomic In Vivo Drosophila Model System.
    Huizar FJ; Hill HM; Bacher EP; Eckert KE; Gulotty EM; Rodriguez KX; Tucker ZD; Banerjee M; Liu H; Wiest O; Zartman J; Ashfeld BL
    ChemMedChem; 2022 Feb; 17(4):e202100512. PubMed ID: 34994084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A).
    Adayev T; Wegiel J; Hwang YW
    Arch Biochem Biophys; 2011 Mar; 507(2):212-8. PubMed ID: 21185805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes.
    Kumar K; Suebsuwong C; Wang P; Garcia-Ocana A; Stewart AF; DeVita RJ
    J Med Chem; 2021 Mar; 64(6):2901-2922. PubMed ID: 33682417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Dual Inhibitor of DYRK1A and GSK3β for β-Cell Proliferation: Aminopyrazine Derivative GNF4877.
    Liu YA; Jin Q; Ding Q; Hao X; Mo T; Yan S; Zou Y; Huang Z; Zhang X; Gao W; Wu TY; Li C; Bursalaya B; Di Donato M; Zhang YQ; Deaton L; Shen W; Taylor B; Kamireddy A; Harb G; Li J; Jia Y; Schumacher AM; Laffitte B; Glynne R; Pan S; McNamara P; Molteni V; Loren J
    ChemMedChem; 2020 Aug; 15(16):1562-1570. PubMed ID: 32613743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DYRK1A Kinase Inhibitors Promote β-Cell Survival and Insulin Homeostasis.
    Barzowska A; Pucelik B; Pustelny K; Matsuda A; Martyniak A; Stępniewski J; Maksymiuk A; Dawidowski M; Rothweiler U; Dulak J; Dubin G; Czarna A
    Cells; 2021 Aug; 10(9):. PubMed ID: 34571911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition.
    Bálint B; Wéber C; Cruzalegui F; Burbridge M; Kotschy A
    ChemMedChem; 2017 Jun; 12(12):932-939. PubMed ID: 28264138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites.
    Frost D; Meechoovet B; Wang T; Gately S; Giorgetti M; Shcherbakova I; Dunckley T
    PLoS One; 2011 May; 6(5):e19264. PubMed ID: 21573099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase.
    Brahmaiah D; Kanaka Durga Bhavani A; Aparna P; Sampath Kumar N; Solhi H; Le Guevel R; Baratte B; Ruchaud S; Bach S; Singh Jadav S; Raji Reddy C; Roisnel T; Mosset P; Levoin N; Grée R
    Bioorg Med Chem; 2021 Feb; 31():115962. PubMed ID: 33422908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
    Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P
    Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A.
    Zhou Q; Reekie TA; Abbassi RH; Indurthi Venkata D; Font JS; Ryan RM; Munoz L; Kassiou M
    Bioorg Med Chem; 2018 Dec; 26(22):5852-5869. PubMed ID: 30401502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic and genetic approaches define human pancreatic β cell mitogenic targets of DYRK1A inhibitors.
    Ackeifi C; Swartz E; Kumar K; Liu H; Chalada S; Karakose E; Scott DK; Garcia-Ocaña A; Sanchez R; DeVita RJ; Stewart AF; Wang P
    JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31821176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.